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ABSTRACT 
Microsatellite instability (MSI) is a unique molecular alteration that is due to a defective DNA mismatch repair 
(MMR) system. Approximately, 15-20 % of sporadic colorectal cancers (CRC) display MSI. Determination of 
MSI status in CRC has prognostic and predictive implications. Additionally, detecting MSI is used diagnostically 
for tumor detection and classification. The present study analyzed a panel of five mononucleotide markers, BAT-
25, BAT-26, NR-21, NR-22 and NR-27, amplified in a single multiplex PCR reaction to evaluate MSI status in 
CRC patients. Genomic DNA from 50 CRC and paired adjacent normal tissues was used for PCR-based MSI 
analysis. Our finding showed microsatellite instability in 36 % of specimens. Instability with differences in allele 
lengths was observed in the tumoral DNA compared to the tumor-free margin DNA sample. The frequency of 
instability in NR-21, BAT-26 and BAT-25 markers were more than others; their frequency were 35.48 %, 29.03 %, 
and 22.58 %, respectively. In conclusion, the NR-21, BAT-26, and BAT-25 were the most useful markers for 
discriminating cancer tissue from normal, therefore these markers have demonstrated promising potential for de-
termining MSI status in patients with sporadic colorectal cancer. 
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INTRODUCTION 
Colorectal cancer (CRC) is the third most 
common cancer in humans and the third lead-
ing cause of cancer related deaths in both gen-
ders, which contributes to a major public 
health problem worldwide (Jemal et al., 2011; 
Siegel et al., 2012). As well, CRC is the third 
and fourth generally diagnosed cancer in Ira-
nian men and women, respectively 
(Mahmodlou et al., 2012). The absence of 
clinical symptoms in patients with CRC until 
the post-cancer stage is one of the most com-
mon hallmarks of the disease, which leads to 
poor prognosis and high mortality (Behrouz 
Sharif et al., 2016). Colorectal cancer is 
mainly developed through the gradual accu-
mulation of genetic and epigenetic changes in 
the genome (Fearon and Vogelstein, 1990). 
Sporadic colorectal cancer is the most 
common type of CRC and includes approxi-
mately 75 % of cases in which there is no ob-
vious evidence of the inherited disorder. 
However, it seems that the genetic factors are 
not definite and the possibility of cancerous 
effects exists even in the absence of specific 
mutations (Arvelo et al., 2015). There are sev-
eral molecular changes in CRC such as Chro-
mosomal Instability (CIN), Microsatellite In-
stability (MSI), and CpG Island Methylator 
phenotype (CIMP) (Worthley and Leggett, 
2010). Most CRCs are developed via the CIN 
pathway, while 15-20 percent of CRC cases 
represent MSI (Vilar and Gruber, 2010; 
Cancer Genome Atlas Network, 2012). 
Microsatellites are short tandem repeat 
(STR) stretches of DNA sequence distributed 
throughout the coding and non-coding re-
gions of the genome, which are susceptible to 
high mutation rates due to their repeated 
structures (Ellegren, 2004). Microsatellite in-
stability (MSI) is a molecular phenotype ris-
ing from faulty DNA mismatch repair (MMR) 
system (Yamamoto and Imai, 2015). DNA 
mismatch repair system corrects fallacious 
deletion, insertion, and base mismatches pro-
duced within DNA replication and recombi-
nation that have escaped the proofreading 
process (Jiricny, 2006). MSI in tumoral DNA 
is defined by the presence of intermittent 
sized repetitive DNA sequences which do not 
exist in the corresponding germ-line DNA. 
The presence of MSI in the colon, gastric, en-
dometrial and the majority of other sporadic 
cancers have been indicated (Yamamoto and 
Imai, 2015). Determining the status of MSI in 
CRC has prognostic and therapeutic out-
comes. Additionally, MSI clinically can be 
used for detection of patients with germline 
defects due to MMR-deficiency and is used 
for tumor diagnosis and classification 
(Setaffy and Langner, 2015).  
MSI is indirectly detected by immuno-
histochemical staining (IHC) by analyzing the 
MMR protein expression, or directly with a 
specific microsatellite repeats amplification 
by PCR-based methods (Buecher et al., 
2013). At first attempt to detect MSI status in 
CRC using the PCR-based methods, which 
are the most common detection ways, the Na-
tional Cancer Institute (NCI) suggested a five 
panel of microsatellite markers included three 
dinucleotide repeats (D5S346, D2S123, and 
D17S250) and two mononucleotide repeats 
(BAT25 and BAT26) (Rodriguez-Bigas et al., 
1997). After a while, it was found that mono-
nucleotide markers are more specific and 
more sensitive than dinucleotide repeats since 
dinucleotide markers have a polymorphic na-
ture (Suraweera et al., 2002) and thus, NCI re-
vised the Bethesda guideline criteria (Umar et 
al., 2004).  
Nowadays, the use of panels containing 
mononucleotide markers has increased with 
respect to their higher sensitivity and specific-
ity for detecting MSI in CRCs (Buhard et al., 
2004; Xicola et al., 2007; Agostini et al., 
2010; Goel et al., 2010; You et al., 2010; 
Cicek et al., 2011; Nojadeh et al., 2018). For 
this reason, our objective in the present study 
is to analyze a panel of five mononucleotide 
markers (BAT-25, BAT-26, NR-21, NR-22 
and NR-27) amplified in a single pentaplex 
PCR reaction to evaluate their combined po-
tential for diagnosing MSI status in CRC pa-
tients. 
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MATERIALS AND METHODS 
Study design and patients 
This cross-sectional study was conducted 
as a cooperation between Tuberculosis and 
Lung Disease Research Center of the Tabriz 
University of Medical Science, Amiral-
momenin and Imam Reza Hospitals, Tabriz, 
Iran. Study participants were Iranians who 
were confirmed with colorectal cancer on the 
basis of clinicopathological findings and all of 
the patients were candidates for cancer sur-
gery. Cases that have undergone chemother-
apy or radiotherapy treatments before surgery 
and have other malignancies, were not in-
cluded in the study. The study was comprised 
of 22 males (44 %) and 28 females (56 %) 
with a median age of 59 years (range, 29–83 
years). The ethical protocol of this study was 
confirmed by the Ethics Committee of Tabriz 
University of Medical Sciences and written 
informed consent was obtained from all pa-
tients to participate in this study.  
 
Tissue specimens 
Fresh tumor and tumor-free margine tis-
sue samples were obtained from 50 sporadic 
colorectal cancer patients who underwent the 
appropriate surgical operation as a routine 
treatment procedure at Amiralmomenin and 
Imam Reza Hospitals from 2015 to 2017. Af-
ter resection, the specimens were immediately 
snap frozen in liquid nitrogen and stored at  
-80 °C until further steps. The tissue samples 
were processed for routine histological and 
pathological examination by the pathologist 
and were divided into two different groups of 
50 tumor samples and 50 margin samples. 
The patients' clinicopathological and demo-
graphic data were collected retrospectively. 
 
DNA extraction 
Genomic DNA was extracted separately 
from tumor and normal tissue samples using 
a standard proteinase-K and Phenol-chloro-
form method. The concentration of the ex-
tracted DNA and quality of the amplifiable 
DNA was measured by NonoDrop spectro-
photometer and agarose gel electrophoresis, 
respectively (Figure 1). Accordingly, ex-
tracted DNA samples which had the final con-
centration of >100 ng/µl and optical density 
(OD260/280) ratio in the range of 1.7-1.9 
were selected for further analysis. 
 
PCR reaction and MSI detection 
MSI was determined by comparing the 
different lengths of specific microsatellite 
markers in tumor cells with their matched ad-
jacent non-cancerous cells using five mono-
nucleotide microsatellite repeats including 
BAT25, BAT26, NR27, NR21, and NR22. 
The 5’ anti-sense primers were end-labeled 
with a fluorescent dye (6-FAM or HEX). The 
primers used for amplification of microsatel-
lite markers were those used in different pre-
vious studies (17, 25-26). Primer sequences 
are presented in Table 1. 
Multiplex PCR was carried out in total 
volume of 25 µl containing 12.5 µl Master 
Mix (RED), 2.4 µl double distilled water, 1.6 
µl DNA and 6 µl primers (0.96 µl of each 
BAT25 and BAT26; 1.44 µl of each NR22 
and NR27; 1.2 µl of NR21). The PCR reac-
tions consisted of an initial 10 minutes for de-
naturation step at 94 °C, followed by 30 con-
tinuous cycles at 94 °C for 15 seconds, 52 °C 
for 30 seconds and 72 °C for 30 seconds, with 
the last extension at 72 °C for 5 minutes. The 
amplified products were then electrophoresed 
on 2 % agarose gel to control the precise size 
and specificity. Subsequently, the fluorescent 
PCR products were analyzed by capillary 
electrophoresis using an ABI 3730XL se-
quencer (Applied Biosystems) and Gene-
mapper analysis software. Tumors with insta-
bility at two or more of five markers com-
pared with adjacent normal tissue were con-
sidered MSI-high (MSI-H), whereas those 
with instability at only one marker were con-
sidered MSI-low (MSI-L). Moreover, tumors 
with no apparent instability at any of these 
markers were considered Microsatellite Sta-
ble (MSS). 
 
 
EXCLI Journal 2018;17:945-951 – ISSN 1611-2156 
Received: June 22, 2018, accepted: September 17, 2018, published: September 24, 2018 
 
 
948 
 
Figure 1: A representative graph of MSI-H profiles obtained with the pentaplex panel (NR-21, BAT-26, 
BAT-25, NR-22, and NR-27) in tumor (T) and matched tumor marginal (M) tissues. It represents insta-
bility for the 4 microsatellite markers (arrows), while no apparent microsatellite instability was detected 
in tumor marginal tissue samples in this study. BAT-26, NR-27, and NR-22 were labeled with FAM, NR-
21 and BAT-26 were labeled with HEX. Abbreviations: M= tumor-free margine tissue; T= tumor tissue. 
 
 
Table 1: primers used for MSI assay 
Average PCR 
product size (bp) 
Label Sense and Antisense primer 
(5’→3’) 
Gene Marker 
124 
 
HEX F: TCGCCTCCAAGAATGTAAGT 
R: TCTGCATTTTAACTATGGCT 
c-kit 
 
BAT-25 
122 6-FAM F: TGACTACTTTTGACTTCAGCC 
R: AACCATTCAACATTTTTAAC 
hMSH2 BAT-26 
89 6-FAM F: AACCATGCTTGCAAACCACT 
R: CGATAATACTAGCAATGAC 
Inhibitor of apopto-
sis protein-1 
NR-27 
104 HEX F: TAAATGTATGTCTCCCCTGG 
R: ATTCCTACTCCGCATTCACA 
SLC7A8 NR-21 
143 6-FAM F: GAGGCTTGTCAAGGACATA 
R: AATTCGGATGCCATCCAGTT 
Transmembrane 
precursor protein B5 
NR-22 
 
Statistical analysis 
The Chi-square test was used to calculate 
the non-parametric data distribution. Statisti-
cal analysis was performed in each group us-
ing the Mann-Whitney U test. The data ob-
tained in this study were analyzed by descrip-
tive statistics (frequency-percentage) and bi-
nomial test. In all tests, P value<0.05 was con-
sidered statistically significant. All analysis 
were performed using the SPSS version 17.  
RESULTS 
Clinicopathological features 
The patients ranged in age from 29 to 83 
years, the mean height and weight of patients 
were about 165 cm and about 71 kg, respec-
tively. Twenty-two of the patients were male. 
There was no family history of colorectal can-
cer in any of the patients. The tumors were lo-
cated in the right colon, transverse colon, left 
colon, sigmoid colon, cecal and rectosigmoid 
regions. The mean size of tumors was 5.6 cm 
(range 3-19 cm). Nine cases were Stage I, 20 
were Stage II, 15 were Stage III, and 6 cases 
were Stage IV. Only 8 cases were active 
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smokers. The pathological features of sam-
ples are displayed in Table 2. There was no 
statistically significant correlation between 
MSI status with clinicopathological features 
of patients. 
 
Table 2: Clinicopathological findings of patients 
Clinicopathological 
features 
Fre-
quency 
P value 
Age 
<50 
>50 
 
9 
41 
0.21 
Gender  
Male 
Female 
 
22 
28 
0.64 
Tumor location 
Right colon 
Transverse colon 
Left colon 
Sigmoid colon 
Cecal 
Rectosigmoid 
 
13 
5 
6 
13 
4 
9 
0.13 
Tumor size (cm) 
<5 
>5 
 
28 
22 
0.56 
Tumor grade 
G1 
G2 
G3 
 
21 
26 
3 
0.29 
Tumor stage* 
Stage I 
Stage II 
Stage III 
Stage IV 
 
9 
20 
15 
6 
0.11 
Smoking 
Yes 
No  
 
8 
42 
0.58 
* In this study, tumor stages were defined considering TNM 
staging guidelines for CRC tumors.
MSI analysis 
MSI was observed in 36 % of the patients. 
Out of 50 tumors included in the study, 8 
(16 %) showed instability at only one marker 
(MSI-L) and 10 (20 %) were MSI-H with in-
stability at two or more than two markers 
(Figure 1). Tumor free margin samples 
demonstrated the absence of MSI regarding 
investigated markers. There was no signifi-
cant relationship between clinical and patho-
logical characteristics of patients with insta-
bility in tumor sites. Our finding demon-
strated that the frequency of NR-21, BAT-26, 
and BAT-25 markers were 35.48 %, 29.03 %, 
and 22.58 %, respectively. Furthermore, our 
results showed that the frequency of NR-22 
and NR-27 markers were similar (Table 3) 
(Figure 2). 
 
 
 
Table 3: The P value of five markers compared to 
each other 
Markers  P value Relationship  
NR-21 0.041 Significant  
BAT-26 0.032 Significant 
BAT-25 0.014 Significant 
NR-22 0.16 Not Significant 
NR-27 0.22 Not Significant 
 
 
 
 
Figure 2: The frequency of microsatellite instability of markers 
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DISCUSSION 
The aim of the present study was to ana-
lyze a panel of five mononucleotide microsat-
ellite markers, BAT-25, BAT-26, NR-21, 
NR-22 and NR-27, amplified in a single mul-
tiplex PCR reaction to evaluate MSI status in 
sporadic CRC patients. 
Approximately, 15-20 % of sporadic col-
orectal cancers and up to 90 % of Lynch syn-
drome (LS) patients display MSI (Goel et al., 
2010). In this study, the frequency of MSI in 
sporadic colorectal cancer was detected in 
36 % of specimens which was higher than 
previous reports (Goel et al., 2010). However, 
in another study performed in North-East Iran 
MSI was detected in 45 % of patients 
(Esmailnia et al., 2014).  
Three different MSI phenotypes by Be-
thesda guideline are described. If two or more 
microsatellite markers are mutated, the tumor 
is considered MSI-high (MSI-H); if only one 
has mutated, the tumor is defined as MSI-low 
(MSI-L); and if none of the loci show insta-
bility, the tumor is considered Microsatellite 
Stable (Rodriguez-Bigas et al., 1997). In the 
present study, 20 % of patients were MSI-H 
which is similar to the previous report 
(Esmailnia et al., 2014). 
Our investigation demonstrated that NR-
21 had the highest sensitivity with 35.48 % in 
our patients. Furthermore, previous studies in 
the Iranian and Slovenian population were 
compatible with our result for this marker 
(Berginc et al., 2009; Goel et al., 2010). We 
observed the frequency of NR-22 and NR-27 
to be the least and the same among the mark-
ers used; these data were compatible with 
Berginc et al. findings in 2009 (Berginc et al., 
2009). BAT-25 was the most sensitive marker 
in the different studies by Leite et al. (2010) 
and Montazer Haghighi et al. (2010) while in 
our study it was not the most instable marker. 
Our study showed that the NR-21, BAT-
26 and BAT-25 markers were the strongest 
markers for the detection of sporadic colorec-
tal cancer, respectively, among the five mark-
ers used. Therefore, it seems that the use of a 
triple panel with three unstable markers can 
be used to determine the status of microsatel-
lite instability in sporadic colorectal cancer 
patients. However, for the final confirmation, 
the ability of these markers to act as a prom-
ising diagnostic marker seems to be a neces-
sity for further studies. 
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